Page last updated: 2024-09-02
tamibarotene and bms453
tamibarotene has been researched along with bms453 in 1 studies
Compound Research Comparison
| Studies (tamibarotene) | Trials (tamibarotene) | Recent Studies (post-2010) (tamibarotene) | Studies (bms453) | Trials (bms453) | Recent Studies (post-2010) (bms453) |
|---|---|---|---|---|---|
| 198 | 10 | 105 | 26 | 0 | 13 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Gronemeyer, H; Kagechika, H; Lou, YR; Miettinen, S; Tuohimaa, P | 1 |
Other Studies
1 other study(ies) available for tamibarotene and bms453
| Article | Year |
|---|---|
Retinoic acid via RARalpha inhibits the expression of 24-hydroxylase in human prostate stromal cells.
Topics: Benzoates; Calcitriol; Cell Line; Cell Line, Tumor; Cells, Cultured; Dibenzazepines; Epithelial Cells; Gene Expression Regulation; Humans; Male; Prostate; Prostatic Neoplasms; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoid X Receptors; Retinoids; Steroid Hydroxylases; Tetrahydronaphthalenes; Transfection; Tretinoin; Vitamin D3 24-Hydroxylase | 2005 |